Stocktoria
Cue Biopharma, Inc. CUE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-01-02
Cue Biopharma, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $27.5M | $9.3M | $5.5M | $1.2M | $14.9M |
| R&D expense | $37.7M | $36.3M | $40.8M | $38.6M | $41.3M |
| Operating income | -$26.6M | -$41.5M | -$52.1M | -$53.2M | -$43.7M |
| Interest expense | $100,000 | $100,000 | $100,000 | $109,000 | — |
| Income tax | $500,000 | $0 | — | $0 | $495,000 |
| Net income | -$26.6M | -$40.7M | -$50.7M | -$53.0M | -$44.2M |
| EPS (diluted) | $-0.28 | $-0.72 | $-1.11 | $-1.49 | $-1.41 |
| Operating cash flow | -$21.7M | -$36.3M | -$40.0M | -$41.8M | -$38.8M |
| Free cash flow | -$21.9M | -$36.4M | -$40.0M | -$42.0M | -$39.8M |
| Cash & equivalents | $27.1M | $22.5M | $48.5M | $51.6M | $64.4M |
| Total assets | $42.2M | $32.2M | $61.5M | $91.3M | $83.4M |
| Total liabilities | $15.8M | $14.7M | $24.4M | $25.6M | $17.9M |
| Shareholders' equity | $26.4M | $17.5M | $37.1M | $65.7M | $65.5M |
Source: SEC EDGAR filings · CIK 0001645460 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.